# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

A 510(k) Number K210793   
B Applicant bioMérieux SA   
C Proprietary and Established Names VIDAS $\textsuperscript { \textregistered }$ NEPHROCHECK®   
D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>PIG</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 862.1220 - AcuteKidney Injury Test System</td><td rowspan=1 colspan=1>CH - ClinicalChemistry</td></tr></table>

II Submission/Device Overview:

A Purpose for Submission: New device

# B Measurand:

The test reports an AKIRISK score derived from the measurement of insulin-like growth factorbinding protein (IGFBP-7) and tissue-inhibitor of metalloproteinases 2 (TIMP-2).

# C Type of Test:

Quantitative Immunoassay

# III Intended Use/Indications for Use:

A Intended Use(s): See Indications for Use below.

# B Indication(s) for Use:

VIDAS $\textsuperscript { \textregistered }$ NEPHROCHECK $\textsuperscript { \textregistered }$ is an automated test for use on the VIDAS $\textsuperscript { \textregistered }$ 3 instrument for the immunoenzymatic quantitative determination of TIMP‑2 (Tissue Inhibitor of Metalloproteinase‑2) and IGFBP‑7 (Insulin-like Growth Factor‑Binding Protein 7) proteins in human urine using the ELFA technique (Enzyme Linked Fluorescent Assay) for calculation of the AKIRISK™ Score.

The VIDAS $\textsuperscript { \textregistered }$ NEPHROCHECK $\textsuperscript { \textregistered }$ assay is intended to be used in conjunction with clinical evaluation in patients who currently have or have had within the past 24 hours acute cardiovascular and or respiratory compromise and are ICU patients as an aid in the risk assessment for moderate or severe acute kidney injury (AKI) within 12 hours of patient assessment. The VIDAS $\textsuperscript { \textregistered }$ NEPHROCHECK $\textsuperscript { \textregistered }$ test is intended to be used in patients 21 years of age or older.

# C Special Conditions for Use Statement(s):

Rx - For Prescription Use Only

The test should not be used as a “standalone test”; test results should be evaluated in the context of all clinical and laboratory data available.

Test results should be used in patients 21 years of age and older.

This test system is for central laboratory use only. It is not for point-of-care use.

# D Special Instrument Requirements:

VIDAS 3 Instrument

# IV Device/System Characteristics:

# A Device Description:

Each VIDAS NEPHROCHECK kit contains 60 tests. The kit is comprised of 60 Reagent Strips, 60 Solid Phase Receptacles (SPR), 1 control, and 1 calibrator (Table 1).

Components of the VIDAS NEPHROCHECK   

<table><tr><td rowspan=1 colspan=2>Kit component</td><td rowspan=1 colspan=1>Description</td></tr><tr><td rowspan=1 colspan=1>60 Reagent Strips</td><td rowspan=1 colspan=1>STR</td><td rowspan=1 colspan=1>Ready-to-use.</td></tr><tr><td rowspan=1 colspan=1>60 SPR devices2 X 30</td><td rowspan=1 colspan=1>SPR</td><td rowspan=1 colspan=1>Ready-to-use.Interior of SPR devices coated with mouse monoclonal IgG anti-1GFBP7 and anti-TIMP-2 + stabilizer of animal origin + preservative.</td></tr><tr><td rowspan=1 colspan=1>S1 Calibrator1 x 1.6 ml (liquid)</td><td rowspan=1 colspan=1>C1</td><td rowspan=1 colspan=1>Ready-to-use.Buffer containing proteins + stabilizer of animal origin + preservative.</td></tr><tr><td rowspan=1 colspan=1>C1 Control1 x 1.2 ml (liquid)</td><td rowspan=1 colspan=1>S1</td><td rowspan=1 colspan=1>Ready-to-use.Buffer containing proteins + stabilizer of animal origin + preservative.</td></tr></table>

The strips consist of 10 wells covered with a labeled foil seal and composed as follows:

Reagent strip components   

<table><tr><td rowspan=1 colspan=1>Well</td><td rowspan=1 colspan=1>Reagents</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Sample well: dispense 100 µL of calibrator, control, or sample.</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>Conjugate: buffer containing alkaline phosphatase-labeled anti-IGFBP-7 monoclonal IgG(mouse) + alkaline phosphatase-labeled anti-TIMP-2 monoclonal IgG (rabbit) + stabilizerof animal origin + preservative.</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>Wash buffer containing preservative</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>Empty well</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>Acid wash buffer</td></tr><tr><td rowspan=1 colspan=1>6-7-8</td><td rowspan=1 colspan=1>Wash buffer containing preservative.</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>Substrate: 4-Methyl-umbelliferyl phosphate (0.6 mmol/L) + preservative.</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>Reading cuvette with substrate: 4-Methyl-umbelliferyl phosphate (0.6 mmol/L) +preservative.</td></tr></table>

# B Principle of Operation:

The assay principle combines a one-step sandwich enzyme immunoassay method with a final fluorescence detection, also known as enzyme-linked fluorescent assay (ELFA). The sample is transferred into the well containing anti‑IGFBP‑7 and anti-TIMP‑2 antibodies labeled with alkaline phosphatase (conjugate). The sample/conjugate mixture is cycled in and out of the Solid Phase Receptacle (SPR) device several times. This operation enables the two proteins to bind with the immunoglobulins that are fixed to the interior wall of the SPR device and to the conjugate to form a sandwich. Unbound components are eliminated during washing steps. Two detection steps are carried out successively. During each detection step, the substrate (4‑Methyl‑umbelliferyl phosphate) is cycled in and out of the SPR device. The conjugate enzyme catalyzes the hydrolysis of this substrate into a fluorescent product (4-Methyl-umbelliferone), the fluorescence of which is measured at $4 5 0 \mathrm { n m }$ . For each protein, the intensity of the fluorescence is proportional to the concentration in the sample. At the end of the assay, the protein concentrations are calculated by the VIDAS $\textsuperscript { \textregistered }$ 3 instrument in relation to the two calibration curves, one corresponding to each protein, and encoded in the MLE (Master Lot Entry) data. The concentration from each protein, TIMP‑2 and IGFBP‑7, is converted into a single numerical result called the AKIRISK Score. The VIDAS $\textsuperscript { \textregistered }$ NEPHROCHECK $\textsuperscript { \textregistered }$ Test result, known as the AKIRISK Score, is automatically calculated by the instrument as the product of the concentrations of the two biomarkers, in $\mathrm { n g / m L }$ , divided by 1000, according to the following formula:

AKIRISK Score $=$ (TIMP‑2 x IGFBP‑7)/1000

# V Substantial Equivalence Information:

A Predicate Device Name(s): NEPHROCHECK Test System

# C Comparison with Predicate(s):

<table><tr><td rowspan=1 colspan=1>Device &amp; Predicate Device(s):</td><td rowspan=1 colspan=1>K210793</td><td rowspan=1 colspan=1>K171482</td></tr><tr><td rowspan=1 colspan=1>Device Trade Name</td><td rowspan=1 colspan=1>VIDAS® NEPHROCHECK®</td><td rowspan=1 colspan=1>NEPHROCHECKTest System</td></tr><tr><td rowspan=1 colspan=1>General Device CharacteristicSimilarities</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Intended Use/Indications forUse</td><td rowspan=1 colspan=1>For use in conjunction with clinicalevaluation in patients who currentlyhave or have had within the past 24hours acute cardiovascular and orrespiratory compromise and are ICUpatients as an aid in the riskassessment for moderate or severeacute kidney injury (AKI) within 12hours of patient assessment. For usein patients 21 years of age or older.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Intended users</td><td rowspan=1 colspan=1>Laboratory healthcare professionals</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Specimen</td><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample volume</td><td rowspan=1 colspan=1>100 μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>TIMP-2 and IGFBP-7</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay principle</td><td rowspan=1 colspan=1>Labeled antibody competitionmethod</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reportable interval for theAKIRISK Score</td><td rowspan=1 colspan=1>20-400 ng/mL for IGFBP-72-25 ng/ml for TIMP-20.04-10.00 for AKIRISK Score</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Cutoff</td><td rowspan=1 colspan=1>0.3 AKIRISK Score</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>General Device CharacteristicDifferences</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Antibody type</td><td rowspan=1 colspan=1>Monoclonal antibodies</td><td rowspan=1 colspan=1>Polyclonal andmonoclonalantibodies</td></tr><tr><td rowspan=1 colspan=1>Assay Technique</td><td rowspan=1 colspan=1>Enzyme-linked fluorescent assay(ELFA</td><td rowspan=1 colspan=1>Sandwichimmunoassaytechnique. Lateralflow withfluorescentdetection.</td></tr><tr><td rowspan=1 colspan=1>Automated Instrument</td><td rowspan=1 colspan=1>VIDAS 3 instrument</td><td rowspan=1 colspan=1>ASTUTE140Meter</td></tr></table>

# VI Standards/Guidance Documents Referenced:

CLSI EP05-A3, Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline - Third Edition   
CLSI EP07-Ed3, Interference Testing in Clinical Chemistry   
CLSI EP09-A3c, Measurement Procedure Comparison and Bias Estimation Using Patient Samples - Third Edition   
CLSI EP12-A2, User Protocol for Evaluation of Qualitative Test Performance; Approved Guideline - Second Edition   
CLSI EP17-A2, Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline – Second Edition   
CLSI EP28-A3c, Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline - Third Edition

# VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

# 1. Precision/Reproducibility:

The device precision was evaluated using a 20-day precision study conducted at 3 clinical laboratories according to CLSI guideline EP05-A3 using 7 pooled native urine samples that included samples below the AKIRISK Score cutoff (Samples S1, S2, and S3), and samples to span the range of the AKIRISK Score (Samples S4, S5, S6, and S7). All samples were tested in duplicate, 2 times per day, for 20 days with a single reagent lot and a single instrument at each site. Each sample was measured 80 times at each site, for a total of 240 measurements per sample. The sponsor assessed Within-Run, Between-Run, Between-Day, and Total Imprecision (Between Site/Instrument/Lot variation).

The sponsor provided information to support the expected imprecision of the individual analytes used in the calculation of the AKIRISK score.

All Sites/Lots $\scriptstyle ( 1 1 = 2 4 0$ )   

<table><tr><td rowspan=2 colspan=1>TestSpecimen</td><td rowspan=2 colspan=1>RiskScoreMean</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between Run</td><td rowspan=1 colspan=2>Between Day</td><td rowspan=1 colspan=2>Total Imprecision(Between-Site/Instrument/Lot)</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>S1</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>18.2</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>22.1</td></tr><tr><td rowspan=1 colspan=1>S2</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>10.5</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>6.7</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>16.1</td></tr><tr><td rowspan=1 colspan=1>S3</td><td rowspan=1 colspan=1>0.19</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>7.3</td></tr><tr><td rowspan=1 colspan=1>S4</td><td rowspan=1 colspan=1>0.71</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>10.2</td></tr><tr><td rowspan=1 colspan=1>S5</td><td rowspan=1 colspan=1>1.73</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>7.9</td></tr><tr><td rowspan=1 colspan=1>S6</td><td rowspan=1 colspan=1>4.28</td><td rowspan=1 colspan=1>0.19</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>5.6</td></tr><tr><td rowspan=1 colspan=1>S7</td><td rowspan=1 colspan=1>7.48</td><td rowspan=1 colspan=1>0.37</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>0.49</td><td rowspan=1 colspan=1>6.5</td></tr></table>

A second study was also performed (8 samples, 2 replicates per run, 2 runs per day, 8 days per lot, 3 lots) that demonstrated that lot-to-lot variation was not a significant contributor to assay imprecision.

<table><tr><td rowspan=2 colspan=1>TestSpecimen</td><td rowspan=2 colspan=1>RiskScoreMean</td><td rowspan=1 colspan=2>Repeatability(Within-runprecision)</td><td rowspan=1 colspan=2>Within-lotPrecision</td><td rowspan=1 colspan=2>Within-laboratoryprecision (between-lot,within-instrument)</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>S1</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>8.7</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>9.7</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>12.0</td></tr><tr><td rowspan=1 colspan=1>S2</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>15.7</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>15.9</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>15.9</td></tr><tr><td rowspan=1 colspan=1>S3</td><td rowspan=1 colspan=1>0.19</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>7.1</td></tr><tr><td rowspan=1 colspan=1>S4</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>7.7</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>8.2</td></tr><tr><td rowspan=1 colspan=1>S5</td><td rowspan=1 colspan=1>0.73</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>8.0</td></tr><tr><td rowspan=1 colspan=1>S6</td><td rowspan=1 colspan=1>1.73</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>8.7</td></tr><tr><td rowspan=1 colspan=1>S7</td><td rowspan=1 colspan=1>4.25</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>0.31</td><td rowspan=1 colspan=1>7.4</td></tr><tr><td rowspan=1 colspan=1>S8</td><td rowspan=1 colspan=1>7.46</td><td rowspan=1 colspan=1>0.37</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>0.55</td><td rowspan=1 colspan=1>7.4</td></tr></table>

2. Linearity:

The reportable range of the AKIRISK Score is 0.04 – 10.0. The component measurements of the AKIRISK score (IGFBP-7 and TIMP-2 measurements) were assessed and found to be linear across the reportable range of the AKIRISK Score. However, the AKIRISK Score itself is not expected to be linear.

Low concentration urine was spike with purified recombinant proteins to measure the hook effect at AKIRISK scores approaching 1000. No high dose hook effect was observed for the AKIRISK Score at these values.

# 3. Analytical Specificity/Interference:

Interference studies were conducted in accordance with CLSI EP07-Ed3 using pooled human urine samples. Interferents were selected from medications, contrast agents, plasma expanders, other urine constituents, isoforms of TIMP and IGFBP, and other biomarkers which have been reported as elevated in the literature in AKI. The sponsor performed testing with substances identified as potentially interfering with IGFBP-7 and TIMP-2. Concentrations were selected based on guidelines in CLSI EP37, expected values for this patient population identified from literature references or concentrations previously tested for similar devices. Two lots of the VIDAS NEPHROCHECK assay were tested using 8 VIDAS 3 instruments. A sample with a high AKIRISK Score, as well as a sample close to the clinical cutoff were used. Interference was defined as any interferents that exhibited greater than $\pm 1 0 \%$ interference in the AKIRISK Score test result.

$\%$ observed interference $=$ [Mean Assay Result (Test Pool) - Mean Assay Result (Control Pool)] Mean Assay Result (Control Pool) x 100

If interference was observed at the highest concentration, the effect of the interference was characterized by a dose-response experiment to determine the degree of interference as a function of the interfering substance concentration.

Test substance and highest concentration tested that did not interfere with assay   

<table><tr><td colspan="3" rowspan="1">performance</td></tr><tr><td colspan="1" rowspan="1">No.</td><td colspan="1" rowspan="1">Test Substance</td><td colspan="1" rowspan="1">Highest concentration testedwith &lt;10% interference (mg/L)</td></tr><tr><td colspan="3" rowspan="1">Contrast Agents</td></tr><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">Visipaque (Iodixanol)</td><td colspan="1" rowspan="1">4,941</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Omniscan (Gadodaimide)</td><td colspan="1" rowspan="1">177</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">Omnipaque (Iohexol)</td><td colspan="1" rowspan="1">14,085</td></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">Magnevist (Gadopentetate Dimeglumine)</td><td colspan="1" rowspan="1">422</td></tr><tr><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">Optiray (Ioversol)</td><td colspan="1" rowspan="1">4,944</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Plasma Expanders</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">Dextran 40</td><td colspan="1" rowspan="1">22</td></tr><tr><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">Pentastarch</td><td colspan="1" rowspan="1">9</td></tr><tr><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">Hydroxyethyl starch</td><td colspan="1" rowspan="1">6</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="2" rowspan="1">Drugs and Other Substances</td></tr><tr><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">Acetaminophen (Paracetamol)</td><td colspan="1" rowspan="1">201</td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">Acetone</td><td colspan="1" rowspan="1">697</td></tr><tr><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">Acetylcysteine</td><td colspan="1" rowspan="1">1665</td></tr><tr><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">Acetyl salicylic acid (Aspirin)</td><td colspan="1" rowspan="1">652</td></tr><tr><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">Acyclovir</td><td colspan="1" rowspan="1">66</td></tr><tr><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">Albumin</td><td colspan="1" rowspan="1">6,900</td></tr><tr><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">Albuterol</td><td colspan="1" rowspan="1">0.4</td></tr><tr><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">Amiodarone</td><td colspan="1" rowspan="1">42</td></tr><tr><td colspan="1" rowspan="1">17</td><td colspan="1" rowspan="1">Ammonia</td><td colspan="1" rowspan="1">1000</td></tr><tr><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">Amoxicillin</td><td colspan="1" rowspan="1">75</td></tr><tr><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">Amphotericin</td><td colspan="1" rowspan="1">82</td></tr><tr><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">Ascorbic acid</td><td colspan="1" rowspan="1">52.5</td></tr><tr><td colspan="1" rowspan="1">21</td><td colspan="1" rowspan="1">Atorvastatin</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">22</td><td colspan="1" rowspan="1">Bicarbonates</td><td colspan="1" rowspan="1">2940</td></tr><tr><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">Bilirubin conjugated</td><td colspan="1" rowspan="1">400</td></tr><tr><td colspan="1" rowspan="1">24</td><td colspan="1" rowspan="1">Bumetanide</td><td colspan="1" rowspan="1">30</td></tr><tr><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">Caffeine</td><td colspan="1" rowspan="1">108</td></tr><tr><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">Caspofungin</td><td colspan="1" rowspan="1">86</td></tr><tr><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">Cefepime</td><td colspan="1" rowspan="1">9</td></tr><tr><td colspan="1" rowspan="1">28</td><td colspan="1" rowspan="1">Ceftriaxone</td><td colspan="1" rowspan="1">840</td></tr><tr><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">Cephalexin</td><td colspan="1" rowspan="1">126</td></tr><tr><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">Ciprofloxacin</td><td colspan="1" rowspan="1">12</td></tr><tr><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">Clopidogrel</td><td colspan="1" rowspan="1">225</td></tr><tr><td colspan="1" rowspan="1">32</td><td colspan="1" rowspan="1">Dexmedetomidine (Precedex)</td><td colspan="1" rowspan="1">0.2</td></tr><tr><td colspan="1" rowspan="1">33</td><td colspan="1" rowspan="1">Diltiazem (Cardizem)</td><td colspan="1" rowspan="1">43</td></tr><tr><td colspan="1" rowspan="1">34</td><td colspan="1" rowspan="1">Dipyrone</td><td colspan="1" rowspan="1">9600</td></tr><tr><td colspan="1" rowspan="1">35</td><td colspan="1" rowspan="1">Dopamine</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">36</td><td colspan="1" rowspan="1">Doripenem</td><td colspan="1" rowspan="1">1050</td></tr><tr><td colspan="1" rowspan="1">37</td><td colspan="1" rowspan="1">Epinephrine</td><td colspan="1" rowspan="1">6</td></tr><tr><td colspan="1" rowspan="1">38</td><td colspan="1" rowspan="1">Ethacryinc acid</td><td colspan="1" rowspan="1">19</td></tr><tr><td colspan="1" rowspan="1">39</td><td colspan="1" rowspan="1">Ethanol</td><td colspan="1" rowspan="1">6000</td></tr><tr><td colspan="1" rowspan="1">40</td><td colspan="1" rowspan="1">Fenoldopam</td><td colspan="1" rowspan="1">484</td></tr><tr><td colspan="1" rowspan="1">No.</td><td colspan="1" rowspan="1">Test Substance</td><td colspan="1" rowspan="1">Highest concentration testedwith &lt;10% interference (mg/L)</td></tr><tr><td colspan="1" rowspan="1">41</td><td colspan="1" rowspan="1">Fentanyl</td><td colspan="1" rowspan="1">100</td></tr><tr><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">Fluconazole</td><td colspan="1" rowspan="1">75</td></tr><tr><td colspan="1" rowspan="1">43</td><td colspan="1" rowspan="1">Fluvastatin</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">Furosemide</td><td colspan="1" rowspan="1">60</td></tr><tr><td colspan="1" rowspan="1">45</td><td colspan="1" rowspan="1">Gentamicin</td><td colspan="1" rowspan="1">30</td></tr><tr><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">Glucose</td><td colspan="1" rowspan="1">9909</td></tr><tr><td colspan="1" rowspan="1">47</td><td colspan="1" rowspan="1">Human Anti-Mouse Antibodies (HAMA)</td><td colspan="1" rowspan="1">2</td></tr><tr><td colspan="1" rowspan="1">48</td><td colspan="1" rowspan="1">Hemoglobin</td><td colspan="1" rowspan="1">60</td></tr><tr><td colspan="1" rowspan="1">49</td><td colspan="1" rowspan="1">Heparin</td><td colspan="1" rowspan="1">21</td></tr><tr><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">Hydralazine</td><td colspan="1" rowspan="1">600</td></tr><tr><td colspan="1" rowspan="1">51</td><td colspan="1" rowspan="1">Hydrochlorothiazide</td><td colspan="1" rowspan="1">6</td></tr><tr><td colspan="1" rowspan="1">52</td><td colspan="1" rowspan="1">Hydrocodone</td><td colspan="1" rowspan="1">0.2</td></tr><tr><td colspan="1" rowspan="1">53</td><td colspan="1" rowspan="1">Hydrocortisone</td><td colspan="1" rowspan="1">720</td></tr><tr><td colspan="1" rowspan="1">54</td><td colspan="1" rowspan="1">Ibuprofen</td><td colspan="1" rowspan="1">500</td></tr><tr><td colspan="1" rowspan="1">55</td><td colspan="1" rowspan="1">Insulin</td><td colspan="1" rowspan="1">0.003</td></tr><tr><td colspan="1" rowspan="1">56</td><td colspan="1" rowspan="1">Ketorolac</td><td colspan="1" rowspan="1">166</td></tr><tr><td colspan="1" rowspan="1">57</td><td colspan="1" rowspan="1">Lansoprazole</td><td colspan="1" rowspan="1">90</td></tr><tr><td colspan="1" rowspan="1">58</td><td colspan="1" rowspan="1">Linezolid</td><td colspan="1" rowspan="1">48</td></tr><tr><td colspan="1" rowspan="1">59</td><td colspan="1" rowspan="1">Lisinopril</td><td colspan="1" rowspan="1">0.3</td></tr><tr><td colspan="1" rowspan="1">60</td><td colspan="1" rowspan="1">Lorazepam</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">61</td><td colspan="1" rowspan="1">Low Molecular Weight Heparin</td><td colspan="1" rowspan="1">30</td></tr><tr><td colspan="1" rowspan="1">62</td><td colspan="1" rowspan="1">Mannitol</td><td colspan="1" rowspan="1">18000</td></tr><tr><td colspan="1" rowspan="1">63</td><td colspan="1" rowspan="1">Metformin</td><td colspan="1" rowspan="1">40</td></tr><tr><td colspan="1" rowspan="1">64</td><td colspan="1" rowspan="1">Methylene blue</td><td colspan="1" rowspan="1">3.9</td></tr><tr><td colspan="1" rowspan="1">65</td><td colspan="1" rowspan="1">Metolazone</td><td colspan="1" rowspan="1">60</td></tr><tr><td colspan="1" rowspan="1">66</td><td colspan="1" rowspan="1">Metoprolol</td><td colspan="1" rowspan="1">5</td></tr><tr><td colspan="1" rowspan="1">67</td><td colspan="1" rowspan="1">Metronidazole</td><td colspan="1" rowspan="1">123</td></tr><tr><td colspan="1" rowspan="1">68</td><td colspan="1" rowspan="1">Midazolam</td><td colspan="1" rowspan="1">3.76</td></tr><tr><td colspan="1" rowspan="1">69</td><td colspan="1" rowspan="1">Morphine</td><td colspan="1" rowspan="1">7.8</td></tr><tr><td colspan="1" rowspan="1">70</td><td colspan="1" rowspan="1">Moxifloxacin</td><td colspan="1" rowspan="1">1200</td></tr><tr><td colspan="1" rowspan="1">71</td><td colspan="1" rowspan="1">Myoglobin</td><td colspan="1" rowspan="1">5</td></tr><tr><td colspan="1" rowspan="1">72</td><td colspan="1" rowspan="1">Nitroglycerin</td><td colspan="1" rowspan="1">0.02</td></tr><tr><td colspan="1" rowspan="1">73</td><td colspan="1" rowspan="1">Norepinephrine</td><td colspan="1" rowspan="1">204</td></tr><tr><td colspan="1" rowspan="1">74</td><td colspan="1" rowspan="1">Omeprazole</td><td colspan="1" rowspan="1">8.4</td></tr><tr><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">Ondansetron</td><td colspan="1" rowspan="1">0.342</td></tr><tr><td colspan="1" rowspan="1">76</td><td colspan="1" rowspan="1">Pancuronium</td><td colspan="1" rowspan="1">8</td></tr><tr><td colspan="1" rowspan="1">77</td><td colspan="1" rowspan="1">Pantoprazole (Protonix)</td><td colspan="1" rowspan="1">85</td></tr><tr><td colspan="1" rowspan="1">78</td><td colspan="1" rowspan="1">Phenobarbital</td><td colspan="1" rowspan="1">690</td></tr><tr><td colspan="1" rowspan="1">79</td><td colspan="1" rowspan="1">Phenylephrine</td><td colspan="1" rowspan="1">30</td></tr><tr><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">Pravastatin</td><td colspan="1" rowspan="1">80</td></tr><tr><td colspan="1" rowspan="1">81</td><td colspan="1" rowspan="1">Prednisone</td><td colspan="1" rowspan="1">3</td></tr><tr><td colspan="1" rowspan="1">82</td><td colspan="1" rowspan="1">Propofol</td><td colspan="1" rowspan="1">48</td></tr><tr><td colspan="1" rowspan="1">83</td><td colspan="1" rowspan="1">Ranitidine</td><td colspan="1" rowspan="1">10.5</td></tr><tr><td colspan="1" rowspan="1">84</td><td colspan="1" rowspan="1">Riboflavin</td><td colspan="1" rowspan="1">12</td></tr><tr><td colspan="1" rowspan="1">85</td><td colspan="1" rowspan="1">Rocuronium</td><td colspan="1" rowspan="1">126</td></tr><tr><td colspan="1" rowspan="1">86</td><td colspan="1" rowspan="1">Salicylic Acid</td><td colspan="1" rowspan="1">599</td></tr><tr><td colspan="1" rowspan="1">87</td><td colspan="1" rowspan="1">Theophylline</td><td colspan="1" rowspan="1">60</td></tr><tr><td colspan="1" rowspan="1">88</td><td colspan="1" rowspan="1">Tobramycin</td><td colspan="1" rowspan="1">33</td></tr><tr><td colspan="1" rowspan="1">89</td><td colspan="1" rowspan="1">Torsemide</td><td colspan="1" rowspan="1">12</td></tr><tr><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">Urobilinogen, synthetic</td><td colspan="1" rowspan="1">12</td></tr><tr><td colspan="1" rowspan="1">91</td><td colspan="1" rowspan="1">Valproic Acid (Valproate)</td><td colspan="1" rowspan="1">499</td></tr><tr><td colspan="1" rowspan="1">92</td><td colspan="1" rowspan="1">Vancomycin</td><td colspan="1" rowspan="1">120</td></tr><tr><td colspan="1" rowspan="1">93</td><td colspan="1" rowspan="1">Vasopressin</td><td colspan="1" rowspan="1">5</td></tr><tr><td colspan="1" rowspan="1">94</td><td colspan="1" rowspan="1">Vecuronium</td><td colspan="1" rowspan="1">21</td></tr><tr><td colspan="1" rowspan="1">95</td><td colspan="1" rowspan="1">Warfarin (Coumadin)</td><td colspan="1" rowspan="1">75</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Common Urine Constituents</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">96</td><td colspan="1" rowspan="1">Calcium</td><td colspan="1" rowspan="1">600</td></tr><tr><td colspan="1" rowspan="1">97</td><td colspan="1" rowspan="1">Chloride</td><td colspan="1" rowspan="1">5,600</td></tr><tr><td colspan="1" rowspan="1">98</td><td colspan="1" rowspan="1">Creatinine</td><td colspan="1" rowspan="1">1,800</td></tr><tr><td colspan="1" rowspan="1">99</td><td colspan="1" rowspan="1">Magnesium</td><td colspan="1" rowspan="1">240</td></tr><tr><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">Phosphate</td><td colspan="1" rowspan="1">2,800*</td></tr><tr><td colspan="1" rowspan="1">101</td><td colspan="1" rowspan="1">Potassium</td><td colspan="1" rowspan="1">4,000</td></tr><tr><td colspan="1" rowspan="1">102</td><td colspan="1" rowspan="1">Sodium</td><td colspan="1" rowspan="1">3,600</td></tr><tr><td colspan="1" rowspan="1">103</td><td colspan="1" rowspan="1">Sulfate</td><td colspan="1" rowspan="1">4,800</td></tr><tr><td colspan="1" rowspan="1">104</td><td colspan="1" rowspan="1">Urea</td><td colspan="1" rowspan="1">23,000</td></tr><tr><td colspan="1" rowspan="1">105</td><td colspan="1" rowspan="1">Uric Acid</td><td colspan="1" rowspan="1">700</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Other Proteins Tested</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">106</td><td colspan="1" rowspan="1">Cystatin C</td><td colspan="1" rowspan="1">3</td></tr><tr><td colspan="1" rowspan="1">107</td><td colspan="1" rowspan="1">Interleukin-18 (IL-18)</td><td colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">108</td><td colspan="1" rowspan="1">Kidney Injury Molecule 1 (KIM 1)</td><td colspan="1" rowspan="1">0.02</td></tr><tr><td colspan="1" rowspan="1">109</td><td colspan="1" rowspan="1">Liver Type Fatty Acid Binding Protein (L-FABP</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">110</td><td colspan="1" rowspan="1">N-acetyl-beta-D glucosaminidase (NAG)</td><td colspan="1" rowspan="1">0.00004</td></tr><tr><td colspan="1" rowspan="1">111</td><td colspan="1" rowspan="1">Neutrophil Gelatinase Associated Lipocalin(NGAL)</td><td colspan="1" rowspan="1">3</td></tr><tr><td colspan="1" rowspan="1">112</td><td colspan="1" rowspan="1">Pi-Glutathione-S-transferase (p-GST)</td><td colspan="1" rowspan="1">0.1</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Potential Cross-Reactive Proteins</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">113</td><td colspan="1" rowspan="1">Insulin like growth factor- Binding Protein 1(IGFBP-1)</td><td colspan="1" rowspan="1">0.1</td></tr><tr><td colspan="1" rowspan="1">114</td><td colspan="1" rowspan="1">Insulin like growth factor- Binding Protein 2(IGFBP.2)</td><td colspan="1" rowspan="1">0.25</td></tr><tr><td colspan="1" rowspan="1">115</td><td colspan="1" rowspan="1">Insulin like growth factor- Binding Protein 3(IGFBP-3)</td><td colspan="1" rowspan="1">1.2</td></tr><tr><td colspan="1" rowspan="1">116</td><td colspan="1" rowspan="1">Insulin like growth factor- Binding Protein 4(IGFBP-4)</td><td colspan="1" rowspan="1">1.2</td></tr><tr><td colspan="1" rowspan="1">117</td><td colspan="1" rowspan="1">Insulin like growth factor- Binding Protein 5(IGFBP-5)</td><td colspan="1" rowspan="1">1.2</td></tr><tr><td colspan="1" rowspan="1">118</td><td colspan="1" rowspan="1">Insulin like growth factor- Binding Protein 6(IGFBP-6)</td><td colspan="1" rowspan="1">1.2</td></tr><tr><td colspan="1" rowspan="1">119</td><td colspan="1" rowspan="1">Insulin like growth factor 1 (IGF-1)</td><td colspan="1" rowspan="1">1.5</td></tr><tr><td colspan="1" rowspan="1">120</td><td colspan="1" rowspan="1">Insulin like growth factor 2 (IGF-2)</td><td colspan="1" rowspan="1">1.5</td></tr><tr><td colspan="1" rowspan="1">121</td><td colspan="1" rowspan="1">Cysteine-rich motor neuron 1 protein (CRIM1)</td><td colspan="1" rowspan="1">1.2</td></tr><tr><td colspan="1" rowspan="1">122</td><td colspan="1" rowspan="1">Agrin</td><td colspan="1" rowspan="1">1.2</td></tr><tr><td colspan="1" rowspan="1">123</td><td colspan="1" rowspan="1">Serine protease HTRA1 (HTRA1)</td><td colspan="1" rowspan="1">1.2</td></tr><tr><td colspan="1" rowspan="1">124</td><td colspan="1" rowspan="1">Insulin-like growth factor binding protein-like1 IGFBPL1</td><td colspan="1" rowspan="1">1.2</td></tr><tr><td colspan="1" rowspan="1">125</td><td colspan="1" rowspan="1">Metalloproteinase inhibitor 1 (TIMP-1)</td><td colspan="1" rowspan="1">3</td></tr><tr><td colspan="1" rowspan="1">126</td><td colspan="1" rowspan="1">Metalloproteinase inhibitor 3 (TIMP-3)</td><td colspan="1" rowspan="1">2.5</td></tr><tr><td colspan="1" rowspan="1">127</td><td colspan="1" rowspan="1">Metalloproteinase Inhibitor 4 (TIMP-4)</td><td colspan="1" rowspan="1">0.6</td></tr><tr><td colspan="1" rowspan="1">128</td><td colspan="1" rowspan="1">Matrix Metalloproteinase-2 (MMP-2)</td><td colspan="1" rowspan="1">0.03</td></tr><tr><td colspan="1" rowspan="1">129</td><td colspan="1" rowspan="1">Matrix Metalloproteinase-9 (MMP-9)</td><td colspan="1" rowspan="1">0.03</td></tr></table>

\* The sponsor claims no interference from phosphate up to $1 { , } 1 0 0 \mathrm { m g / L }$ in their labeling despite testing a higher concentration.

Due to the potential of hemoglobin to interfere with results, urine samples with AKIRISK Scores between 0.30 and 0.46 should also be tested with a urine dipstick test for the presence of hematuria. If the blood result is high positive $( 3 + )$ or the urine sample has some indications of blood in the urine (e.g., pink/red color), the AKIRISK Score may be falsely elevated, and should not be used. Hemoglobin levels above $6 0 \mathrm { m g / L }$ can lead to a $20 \%$ increase in the AKIRISK™ Score.

The effect of pH on AKIRISK Scores around and above the cutoff using samples with AKIRISK Score of 0.3 and 5.0 were evaluated. Pooled human urine samples targeting these AKIRISK Scores were adjusted to target pH values of approximately 4, 6, 8, and 10. There was no significant interference detected at any tested pH level.

# 4. Assay Reportable Range:

The analytical measuring interval was determined in the linearity and detection limit studies, which support the analytical measuring interval for AKIRISK Score as 0.04 – 10, corresponding to the AKIRISK Score calculation with the two lower limits and the two upper limits of the protein ranges.

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

Metrological Traceability:

The IGFBP-7 and TIMP-2 values obtained with the VIDAS NEPHROCHECK assay were assigned to be traceable to the commercially available predicate device.

# Sample Stability:

Sample stability studies were reviewed and found acceptable. Urine samples should be centrifuged within 1 hour of collection. The results support the storage of centrifuged samples for up to 5 hours at $1 8 { - } 2 5 ^ { \circ } \mathrm { C }$ in plastic tubes with no additives, or in Low Protein

Binding tubes for up to 5 hours at $1 8 { - } 2 5 ^ { \circ } \mathrm { C }$ , 24 hours at $2 { - } 8 ^ { \circ } \mathrm { C }$ , and 6 months at $\le 6 0 ^ { \circ } \mathrm { C }$ (with up to two freeze-thaw cycles).

# 6. Detection Limit:

Detection limit studies were conducted in accordance with CLSI EP17-A2. Three lots of the assay and 1 instrument were used in the studies. One calibration was performed for each lot of the assay.

# 1. Limit of blank (LoB):

The LoB of each protein was determine using 4 urine samples, tested in duplicate in a single run per day for 8 days, corresponding to 64 values for each of the blank samples.

2. Limit of detection (LoD) and limit of quantitation $( L o Q )$

The LoD and LoQ of IGFBP-7 were determined using 4 individual urine samples obtained from individual healthy donors. The LoD and LoQ of TIMP-2 were determined using 5 individual urine samples obtained from individual healthy donors. Low-level samples were tested in five replicates in a single run per day for 8 days, corresponding to 40 values per sample. The LoD was determined for each lot and each protein consistent with the classical approach described in CLSI EP17-A2. The final LoD for each protein was defined as the maximum LoD value obtained for any of the lots. The final LoD for the VIDAS NEPHROCHECK assay was defined as the AKIRISK Score calculated with the LoD defined for the two proteins by applying the Score formula.

The classical approach described in the CLSI EP17-A2 was used to determine the LoQ. For each lot and each protein the LoQ was defined as $20 \%$ total within-lot precision. The final LoQ for each protein was defined as the maximum LoQ value obtained for any of the lots. The final LoQ for the VIDAS NEPHROCHECK assay was defined as the AKIRISK Score calculated with the LoQ defined for the two proteins by applying the Score formula.

The results are presented below.

Detection limits   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>AKIRISKScore</td></tr><tr><td rowspan=1 colspan=1>LoB</td><td rowspan=1 colspan=1>0.002</td></tr><tr><td rowspan=1 colspan=1>LoD</td><td rowspan=1 colspan=1>0.003</td></tr><tr><td rowspan=1 colspan=1>LoQ</td><td rowspan=1 colspan=1>0.003</td></tr></table>

# 7. Assay Cut-Off:

The assay cut-off is an AKIRISK score of 0.3. This single cut-off value is based on the package insert of the predicate device, as well as the literature, and was validated in the clinical study.

# B Comparison Studies:

1. Method Comparison with Predicate Device:

Not applicable. Please refer to section VII.C below.

Not applicable. The assay is intended for use with urine samples only.

# C Clinical Studies:

The sponsor conducted a retrospective, multi-center clinical study. Sample sets previously collected in the US from two distinct cohorts were used: A) a sample subset of 400 banked human urine samples from Study A (called Cohort A, or Topaz cohort), and B) a sample set of 126 banked urine samples from Study B (called Cohort B, or Opal cohort). The complete Cohort A and Cohort B were previously evaluated in the predicate’s clinical study DEN130031. The subjects in the study were 21 years or older and were ICU patients with respiratory and/or cardiovascular compromise. AKI status for each subject was determined by clinical diagnosis established through independent central adjudication. The Cohort A subset included 69 AKIpositive and 331 non-AKI patients (one of which was excluded due to sample turbidity, resulting in 330 non-AKI patients). The samples available for evaluation were representative of the overall cohort. Cohort B included 29 AKI-positive patients and 97 non-AKI patients. The banked samples were tested at 4 testing sites.

Four lots of the assay were used at each site and 2 calibration cycles per lot were performed.

Comparison of AKIRISK Score $> 0 . 3 0$ and $\mathbf { \ d } \mathbf { \ d } \mathbf { \ d } \mathbf { \ d } \mathbf { \ d } \mathbf { \ d }$ to AKI Status for the subset of Cohort A   

<table><tr><td rowspan=2 colspan=1>Subset of Cohort A</td><td rowspan=1 colspan=2>AKI status</td><td rowspan=2 colspan=1>Total number ofVIDASNEPHROCHECKtest results</td></tr><tr><td rowspan=1 colspan=1>AKI</td><td rowspan=1 colspan=1>No AKI</td></tr><tr><td rowspan=1 colspan=1>AKIRISK Score&gt; 0.30</td><td rowspan=1 colspan=1>62True Positive</td><td rowspan=1 colspan=1>181False Positive</td><td rowspan=1 colspan=1>243</td></tr><tr><td rowspan=1 colspan=1>AKIRISK Score&lt; 0.30</td><td rowspan=1 colspan=1>7False Negative</td><td rowspan=1 colspan=1>149True Negative</td><td rowspan=1 colspan=1>156</td></tr><tr><td rowspan=1 colspan=1>Total number of VIDASNEPHROCHECK test results</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>330</td><td rowspan=1 colspan=1>399</td></tr></table>

Performance characteristic of the subset of Cohort A   

<table><tr><td rowspan=1 colspan=1>Performance characteristic</td><td rowspan=1 colspan=1>Value</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Sensitivity (TPR)</td><td rowspan=1 colspan=1>89.9%</td><td rowspan=1 colspan=1>[80.5 - 95.0]%</td></tr><tr><td rowspan=1 colspan=1>Specificity (TNR)</td><td rowspan=1 colspan=1>45.2%</td><td rowspan=1 colspan=1>[39.9 - 50.5]%</td></tr><tr><td rowspan=1 colspan=1>NPV</td><td rowspan=1 colspan=1>95.5%</td><td rowspan=1 colspan=1>[91.0  -98.2]%</td></tr><tr><td rowspan=1 colspan=1>PPV</td><td rowspan=1 colspan=1>25.5%</td><td rowspan=1 colspan=1>[20.4  -31.3]%</td></tr><tr><td rowspan=1 colspan=1>False Positive Rate (FPR)</td><td rowspan=1 colspan=1>54.8%</td><td rowspan=1 colspan=1>[49.5 - 60.1]%</td></tr><tr><td rowspan=1 colspan=1>False Negative Rate (FNR)</td><td rowspan=1 colspan=1>10.1%</td><td rowspan=1 colspan=1>[5.0 - 19.5]%</td></tr></table>

Comparison of AKIRISK Score $> 0 . 3 0$ and $\mathbf { \ d } \mathbf { \ d } \mathbf { \ d } \mathbf { \ d } \mathbf { \ d } \mathbf { \ d }$ to AKI Status for Cohort B   

<table><tr><td rowspan=2 colspan=1>Opal Cohort</td><td rowspan=1 colspan=2>AKI status</td><td rowspan=2 colspan=1>Total number ofVIDASNEPHROCHECKtest results</td></tr><tr><td rowspan=1 colspan=1>AKI</td><td rowspan=1 colspan=1>No AKI</td></tr><tr><td rowspan=1 colspan=1>AKIRISK Score&gt; 0.30</td><td rowspan=1 colspan=1>24True Positive</td><td rowspan=1 colspan=1>58False Positive</td><td rowspan=1 colspan=1>82</td></tr><tr><td rowspan=1 colspan=1>AKIRISK Score&lt; 0.30</td><td rowspan=1 colspan=1>5False Negative</td><td rowspan=1 colspan=1>39True Negative</td><td rowspan=1 colspan=1>44</td></tr><tr><td rowspan=1 colspan=1>Total number of VIDASNEPHROCHECK test results</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>97</td><td rowspan=1 colspan=1>126</td></tr></table>

Performance characteristic of Cohort B   

<table><tr><td rowspan=1 colspan=1>Performance characteristic</td><td rowspan=1 colspan=1>Value</td><td rowspan=1 colspan=1>95%CI</td></tr><tr><td rowspan=1 colspan=1>Sensitivity (TPR)</td><td rowspan=1 colspan=1>82.8%</td><td rowspan=1 colspan=1>[65.5 - 92.4]%</td></tr><tr><td rowspan=1 colspan=1>Specificity(TNR)</td><td rowspan=1 colspan=1>40.2%</td><td rowspan=1 colspan=1>[31.0 - 50.2]%</td></tr><tr><td rowspan=1 colspan=1>NPV</td><td rowspan=1 colspan=1>88.6%</td><td rowspan=1 colspan=1>[76.0 - 95.0]%</td></tr><tr><td rowspan=1 colspan=1>PPV</td><td rowspan=1 colspan=1>29.3%</td><td rowspan=1 colspan=1>[20.5 - 39.9]%</td></tr><tr><td rowspan=1 colspan=1>FPR (1-Specificity)</td><td rowspan=1 colspan=1>59.8%</td><td rowspan=1 colspan=1>[49.8 - 69.0]%</td></tr><tr><td rowspan=1 colspan=1>FNR (1-Sensitivity)</td><td rowspan=1 colspan=1>17.2%</td><td rowspan=1 colspan=1>[7.6 - 34.5]%</td></tr></table>

1. Clinical Sensitivity: See above.

2. Clinical Specificity: See above.

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): Not applicable.

# D Clinical Cut-Off:

The clinical cutoff is an AKIRISK Score $> 0 . 3 0$ . Please refer to section VII.C above.

# E Expected Values/Reference Range:

A reference range study was conducted in accordance with CLSI EP28-A3. Banked urine samples from apparently healthy US subjects (378) and US subjects with stable chronic morbidities (372), were tested at 3 sites. Three assay lots were used per site and 2 calibration cycles per lot were performed. The overall reference interval for apparently healthy subjects was $< 0 . 0 4$ to 2.50 and for subjects with stable chronic morbidities was $< 0 . 0 4$ to 2.66. The reference intervals were comparable for apparently healthy subjects and subjects with stable chronic morbidities, and for males and females from the two cohorts. A breakdown by sex is shown below.

Reference range across different groups   

<table><tr><td rowspan=1 colspan=1>Cohort</td><td rowspan=1 colspan=1>Gender</td><td rowspan=1 colspan=1>Number of subjects</td><td rowspan=1 colspan=2>AKIRISK ScoreCentral 95% Interval</td></tr><tr><td rowspan=3 colspan=1>Apparently HealthySubjects</td><td rowspan=1 colspan=1>Female</td><td rowspan=1 colspan=1>191</td><td rowspan=1 colspan=2>&lt;0.04,2.81]</td></tr><tr><td rowspan=1 colspan=1>Male</td><td rowspan=1 colspan=1>187</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>&lt;0.04 , 3.06 ]</td></tr><tr><td rowspan=1 colspan=1>All</td><td rowspan=1 colspan=1>378</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>&lt;0.04 , 2.50]</td></tr><tr><td rowspan=3 colspan=1>Subjects with StableChronic Morbidities</td><td rowspan=1 colspan=1>Female</td><td rowspan=1 colspan=1>191</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>&lt;0.04 , 2.91 ]</td></tr><tr><td rowspan=1 colspan=1>Male</td><td rowspan=1 colspan=1>181</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>All</td><td rowspan=1 colspan=1>372</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr></table>

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.